BridgeBio Oncology Therapeutics will present at two investor conferences in September, highlighting its focus on RAS-pathway malignancies.
Quiver AI Summary
BridgeBio Oncology Therapeutics, Inc. (BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, announced that its leadership will participate in two upcoming investor conferences in September. The events include a fireside chat at the Cantor Global Healthcare Conference on September 4 and another at the Morgan Stanley Global Healthcare Conference on September 8, both in New York. Investors can find links for live webcasts and replays on BBOT's website, where replays will be available for at least 90 days post-event. The company aims to enhance cancer treatment through a pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies.
Potential Positives
- Participation in well-known investor conferences enhances visibility and credibility in the investment community.
- Opportunity for leadership to engage directly with investors may boost investor confidence and attract potential funding.
- Company's focus on improving outcomes for cancer patients highlights a strong commitment to addressing significant health challenges.
- Availability of webcasts and replays increases accessibility and engagement for stakeholders interested in the company's developments.
Potential Negatives
- None
FAQ
What investor conferences is BridgeBio Oncology attending in September?
BridgeBio Oncology will participate in the Cantor Global Healthcare Conference on September 4 and the Morgan Stanley Global Healthcare Conference on September 8.
When can I watch the live webcasts for the conferences?
Live webcasts will be available on the "Investors" page of the BBOT website during the conferences.
How long will the replays of the conference events be available?
Replays of the conference events will be available on the website for at least 90 days following each event.
What is the focus of BridgeBio Oncology's research?
BridgeBio Oncology focuses on developing therapeutics targeting RAS and PI3Kα malignancies to improve cancer patient outcomes.
How can I contact BridgeBio Oncology for investor inquiries?
You can contact BridgeBio Oncology's Chief Financial Officer, Uneek Mehra, at [email protected] for investor inquiries.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BBOT Analyst Ratings
Wall Street analysts have issued reports on $BBOT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wedbush issued a "Outperform" rating on 08/18/2025
To track analyst ratings and price targets for $BBOT, check out Quiver Quantitative's $BBOT forecast page.
Full Release
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in September.
Details of the company’s participation are as follows:
-
Cantor Global Healthcare Conference
- Fireside Chat: Thursday, September 4 at 8:35 a.m. ET as well as hosting investor meetings in New York
-
Morgan Stanley Global Healthcare Conference
- Fireside Chat: Monday, September 8 at 7:45 a.m. ET as well as hosting investor meetings in New York
Links for live webcasts and replays, if available, will be available in the on the “Investors” page of the BBOT website. Replays will be available on the website for at least 90 days following the event.
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit
www.bbotx.com
and follow us on
LinkedIn
.
BBOT Contacts:
Investor Contact:
Uneek Mehra, Chief Financial Officer
BBOT
[email protected]
Media Contact:
Jake Robison
Inizio Evoke Comms
[email protected]
